Skip to main content

Table 2 Baseline CMR characteristics of patients and controls

From: Myocardial triglycerides in cardiac amyloidosis assessed by proton cardiovascular magnetic resonance spectroscopy

  Amyloidosis Controls P-value
LVEF (%) 60.0 ± 13.2 66.1 ± 4.3 0.170
IVS (mm) 18.0 ± 4.6 8.0 ± 1.5 < 0.001
LVMi(g/m2) 85.2 ± 25.1 45.0 ± 8.7 < 0.001
LVEDV (mL) 130.1 ± 23.0 126.9 ± 34.0 0.8
LVEDD (mm) 46.2 ± 3.5 46.9 ± 4.6 0.678
SV (mL) 76.7 ± 16.3 84.5 ± 20.2 0.331
RVEF (%) 64.5 ± 9.5 62.8 ± 5.0 0.604
RVEDV (mL) 112.0 ± 30.5 130.1 ± 29.3 0.171
GLS (%) −19.7 ± 5.6 −31.1 ± 5.5 < 0.001
GCS (%) −29.8 ± 6.1 −36.2 ± 3.3 0.007
Long SRe 1.7 ± 0.5 1.4 ± 0.4 0.076
Circ SRe 1.3 ± 0.3 1.7 ± 0.4 0.019
  1. Circ circumferential, GLS global longitudinal strain, GCS global circumferential strain, IVS interventricular septum, Long longitudinal, LVEDD left ventricular end-diastolic diameter, LVEDV/RVEDV left/right ventricular end-diastolic volume, LVEF/RVEF left/right ventricular ejection fraction, LVMi left ventricular mass indexed to body surface area, SRe strain rate, SV stroke volume